Events

Field Safety Notices about Subset of Medtronic Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and Implantable Cardioverter Defibrillators (ICDs)

According to Health Sciences Authority (HSA), this field safety notices involved a device in Singapore that was produced by Medtronic International Limited.

What is this?

Field safety notices are communications sent out by medical device manufacturers or their representatives in relation to actions that they may be taking in relation to their product that is on the market. These are mainly for health workers, but also for users. They can include recalls and alerts.

Learn more about the data here
  • Type of Event
    Field Safety Notice
  • Event ID
    600:41/01-009/18/03_35
  • Date
    2018-03-07
  • Event Country
    Singapore
  • Event Source
    HSA
  • Event Source URL
    https://www.hsa.gov.sg/announcements
  • Notes / Alerts
    Data from Singapore is current through September 2018. All of the data comes from the Health Sciences Authority (HSA), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Singapore.
  • Extra notes in the data
    Medtronic Inc

Device

Subset of Medtronic Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and Implantable Car...
  • Model / Serial
  • Product Description
    Subset of Medtronic Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and Implantable Cardioverter Defibrillators (ICDs), Medtronic Inc
  • Manufacturer
    Medtronic International Limited

Manufacturer

Medtronic International Limited
  • Manufacturer Parent Company (2017)
    Medtronic plc
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HSAHSA